No Data
No Data
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Ping An Securities: Maintaining the “Recommended” Rating of Hewang Pharmaceutical (00013.HK), 2023 results are in line with expectations
Ping An Securities released a research report stating that considering that the indications for the company's listed products are still expanding, and the pipeline valuation is expected to further improve, maintaining the “recommended” rating of Hehuang Pharmaceutical (00013.HK), the main business revenue for 2024-2026 is estimated to be US$6.71, 8.61, and 1,027 million US dollars, respectively, and net profit of -1.07, 0.2, and 95 million US dollars, respectively, in line with the previous one. The company's total revenue in 2023 was US$838 million (yoy+97%), of which the comprehensive revenue from the oncology/immunology business was US$529 million (yoy+223)
Hutchison Pharmaceutical (0013.HK): 23-year performance is in line with expectations, intensive catalysis in the global innovation pipeline
Matters: On April 8, 2024, Hutchison Pharmaceutical announced its 2023 annual report. The company's total revenue was US$838 million (yoy +97%), of which the comprehensive revenue from the oncology/immunology business was US$529 million (yoy+
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
No Data